Categories
Tags
Authors: Ader F, Hites M, Poissy J, Belhadi D, Diallo A, Staub T PMID: 34534511 PMCID: PMC8439621 DOI: 10.1016/S1473-3099(21)00485-0 Abstract Background: The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial. We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with standard of care alone in patients admitted to hospital [...]
Categories: MATH+
Tags: COVID-19
Authors: Draghici S, Nguyen TM, Sonna LA, Ziraldo C, Vanciu R, Fadel R et al. PMID: 33693506 PMCID: PMC7989618 DOI: 10.1093/bioinformatics/btab163 Abstract Motivation: COVID-19 has several distinct clinical phases: a viral replication phase, an inflammatory phase and in some patients, a hyper-inflammatory phase. High mortality is associated with patients developing cytokine storm syndrome. Treatment of [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, Methylprednisolone
Authors: Elamir YM, Amir H, Lim S, Rana Y, Lopez CG, Omar A PMID: 34508882 PMCID: PMC8425676 DOI: 10.1016/j.bone.2021.116175 Abstract The systemic illness associated with SARS-CoV-2 infection results in hospitalization rate of 380.3 hospitalizations per 100,000 population, overwhelming health care systems. Vitamin D regulates expression of approximately 11,000 genes spanning many physiologic functions that include [...]
Categories: I-CARE Early Covid, MATH+
Tags: Calcitriol
Authors: Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V PMID: 34480861 PMCID: PMC8409066 DOI: 10.1016/S2213-2600(21)00331-3 Abstract Background: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with [...]
Categories: MATH+
Tags: COVID-19
Authors: Patrick R Lawler, Ewan C Goligher, Jeffrey S Berger, Matthew D Neal, Bryan J McVerry, Jose C Nicolau, et al. PMID: 34351721 PMCID: PMC8362594 DOI: 10.1056/NEJMoa2105911 Abstract Background: Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve [...]
Categories: MATH+
Tags: COVID-19
Authors: Nejat R, Sadr AS, Freitas BT, Murray J, Pegan SD PMID: 34319871 DOI: 10.18433/jpps31931 Abstract Purpose: SARS-CoV-2 infection is associated with substantial mortality and high morbidity. This study tested the effect of angiotensin II type I receptor blocker, losartan, on SARS-CoV-2 replication and inhibition of the papain-like protease of the virus. Methods: The dose-dependent [...]
Categories: MATH+
Tags: losartan, SARS-CoV-2
Authors: McCoy J, Goren A, Cadegiani FA, Vano-Galvan S, Kovacevic M, Situm M et al. PMID: 34350193 PMCID: PMC8326462 DOI: 10.3389/fmed.2021.668698 Abstract Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could [...]
Categories: I-CARE Early Covid, MATH+
Tags: COVID-19, Proxalutamide
Authors: Zhao J, Yang Y, Huang H, Li D, Gu D PMID: 32750119 PMCID: PMC7454371 DOI: 10.1093/cid/ciaa1150 Abstract To explore any relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility, we compared ABO blood group distributions in 2173 COVID-19 patients with local control populations, and found that blood group A was [...]
Categories: MATH+
Tags: COVID-19, SARS-CoV-2
Authors: Tomassa-Irriguible TM, Lielsa-Berrocal L PMID: 34243781 PMCID: PMC8269403 DOI: 10.1186/s12937-021-00727-z Abstract There are limited proven therapeutic options for the prevention and treatment of COVID-19. We underwent an observational study with the aim of measure plasma vitamin C levels in a population of critically ill COVID-19 adult patients who met ARDS criteria according to the [...]
Categories: MATH+
Authors: Hill A, Garratt A, Levi J, Falconer J, Ellis L, McCann K et al. PMID: 34796244 PMCID: PMC8420640 DOI: 10.1093/ofid/ofab358 Abstract Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis investigated ivermectin [...]
Categories: I-CARE Early Covid, MATH+
Tags: ivermectin, SARS-CoV-2